deltatrials
Completed PHASE3 NCT00039871

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

PEG-Intron Plus REBETOL for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Alpha Interferon Treatment in Combination With Ribavirin)

Sponsor: Merck Sharp & Dohme LLC

Conditions Fibrosis Hepatitis Hepatitis C, Chronic Liver Cirrhosis
Interventions PegIntron (peginterferon alfa-2b; SCH 54031) REBETOL (ribavirin; SCH 18908)
Updated 7 times since 2017 Last updated: Mar 7, 2017 Started: May 31, 2002 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

A PHASE3 clinical study on Fibrosis and Hepatitis, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 7 data snapshots since 2002. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.